What is Cytek Biosciences' operating income?

Cytek Biosciences' total operating income in 2025 was -$40.38 million, based on the following breakdown: Total Gross Profit: $104.46 million Total Operating Expenses: $144.84 million

Cytek Biosciences (CTKB) Financials

$4.58 -0.04 (-0.87%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$4.57 -0.01 (-0.24%)

As of 07/20/2026 07:56 PM Eastern

Compare

Annual Income Statements for Cytek Biosciences

This table shows Cytek Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	3.22	0.00	2.58	-12	-6.02	-67
Consolidated Net Income / (Loss)	19	3.03	2.48	-12	-6.02	-67
Net Income / (Loss) Continuing Operations	19	3.03	2.48	-12	-6.02	-67
Total Pre-Tax Income	14	5.94	1.26	-16	-5.70	-30
Total Operating Income	14	9.16	-1.80	-28	-21	-40
Total Gross Profit	52	79	101	109	111	104
Total Revenue	93	128	164	193	200	201
Operating Revenue	93	128	164	193	200	201
Total Cost of Revenue	41	49	63	84	89	97
Operating Cost of Revenue	41	49	63	84	89	97
Total Operating Expenses	38	70	103	137	132	145
Selling, General & Admin Expense	9.37	21	35	44	43	59
Marketing Expense	15	25	33	49	49	49
Research & Development Expense	14	24	35	44	39	36
Total Other Income / (Expense), net	0.77	-3.22	3.06	12	15	11
Interest Expense	0.33	1.74	2.57	2.07	-5.24	0.47
Interest & Investment Income	0.11	0.05	4.62	6.41	5.12	2.22
Other Income / (Expense), net	0.99	-1.53	1.02	7.79	4.46	8.80
Income Tax Expense	-4.98	2.91	-1.22	-3.56	0.32	37
Net Income / (Loss) Attributable to Noncontrolling Interest	16	3.03	-0.09	0.00	0.00	0.00
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-	0.00	-0.02	0.03	-	-0.06
Weighted Average Basic Shares Outstanding	29.13M	76.74M	134.51M	135.28M	130.61M	127.75M
Weighted Average Diluted Shares Outstanding	32.60M	81.54M	138.56M	135.28M	130.61M	127.75M
Weighted Average Basic & Diluted Shares Outstanding	-	134.08M	135.43M	130.82M	128.10M	128.55M

This table shows Cytek Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-6.46	5.50	-6.17	-10	0.94	9.64	-11	-5.58	-5.48	-44	-19
Consolidated Net Income / (Loss)	-6.46	5.50	-6.17	-10	0.94	9.64	-11	-5.58	-5.48	-44	-19
Net Income / (Loss) Continuing Operations	-6.46	5.50	-6.17	-10	0.94	9.64	-11	-5.58	-5.48	-44	-19
Total Pre-Tax Income	-4.19	4.11	-8.99	-7.19	0.16	10	-11	-6.78	-7.77	-4.03	-17
Total Operating Income	-6.42	-0.14	-11	-8.53	-4.25	2.99	-15	-11	-9.19	-5.59	-18
Total Gross Profit	27	33	23	25	29	34	20	24	28	33	21
Total Revenue	48	58	45	47	52	57	41	46	52	62	44
Operating Revenue	48	58	45	47	52	57	41	46	52	62	44
Total Cost of Revenue	21	25	22	21	22	24	21	22	25	29	23
Operating Cost of Revenue	21	25	22	21	22	24	21	22	25	29	23
Total Operating Expenses	34	33	34	34	33	31	35	34	37	38	40
Selling, General & Admin Expense	10	11	11	12	11	9.07	13	14	16	16	18
Marketing Expense	12	12	13	12	12	12	13	12	12	13	12
Research & Development Expense	11	11	9.80	10	9.88	9.72	9.73	8.83	8.96	8.96	9.60
Total Other Income / (Expense), net	2.24	4.25	1.74	1.34	4.41	7.34	3.71	3.85	1.42	1.56	1.09
Interest Expense	0.60	0.39	0.44	0.13	0.12	-5.93	0.29	0.41	0.49	-0.73	0.26
Interest & Investment Income	1.62	1.45	1.36	1.42	1.43	0.91	0.51	0.56	0.57	0.58	0.79
Other Income / (Expense), net	1.21	3.19	0.82	0.06	3.09	0.49	3.49	3.71	1.34	0.26	0.57
Income Tax Expense	2.27	-1.39	-2.82	3.25	-0.78	0.68	0.14	-1.19	-2.29	40	1.49
Weighted Average Basic Shares Outstanding	136.17M	135.28M	130.92M	131.44M	131.00M	130.61M	128.34M	126.93M	127.55M	127.75M	128.70M
Weighted Average Diluted Shares Outstanding	136.17M	135.28M	130.92M	131.44M	132.79M	130.61M	128.34M	126.93M	127.55M	127.75M	128.70M
Weighted Average Basic & Diluted Shares Outstanding	135.55M	130.82M	131.27M	131.51M	128.81M	128.10M	126.66M	127.22M	127.86M	128.55M	129.14M

This table details how cash moves in and out of Cytek Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	136	198	-65	-132	-69	-7.89
Net Cash From Operating Activities	15	4.63	-12	5.28	25	-4.69
Net Cash From Continuing Operating Activities	15	4.63	-12	5.28	25	-4.69
Net Income / (Loss) Continuing Operations	19	3.03	2.48	-12	-6.02	-67
Consolidated Net Income / (Loss)	19	3.03	2.48	-12	-6.02	-67
Depreciation Expense	0.60	1.24	2.49	6.05	7.21	7.58
Amortization Expense	0.00	0.00	3.09	-3.48	-1.93	-1.28
Non-Cash Adjustments To Reconcile Net Income	2.68	9.01	17	22	18	23
Changes in Operating Assets and Liabilities, net	-7.43	-8.65	-38	-7.39	8.03	33
Net Cash From Investing Activities	-1.55	-21	-56	-94	-83	10
Net Cash From Continuing Investing Activities	-1.55	-21	-56	-94	-83	10
Purchase of Property, Plant & Equipment	-1.55	-4.36	-9.75	-4.65	-3.53	-4.08
Acquisitions	0.00	-17	-0.12	-45	-0.68	-0.11
Purchase of Investments	0.00	0.00	-46	-176	-274	-278
Sale of Property, Plant & Equipment	-	-	0.00	0.00	0.29	0.25
Sale and/or Maturity of Investments	-	0.00	0.00	132	195	292
Net Cash From Financing Activities	123	214	5.51	-42	-16	-13
Net Cash From Continuing Financing Activities	123	214	5.51	-42	-16	-13
Repayment of Debt	-1.31	-2.77	-0.05	-0.57	-0.56	-4.75
Repurchase of Common Equity	-	0.00	0.00	-44	-22	-15
Issuance of Debt	0.00	0.00	2.98	0.00	4.18	5.58
Issuance of Common Equity	0.00	216	-	1.86	1.70	1.15
Other Financing Activities, net	4.25	0.64	2.58	1.05	0.46	-0.35
Effect of Exchange Rate Changes	-0.59	1.30	-2.49	-1.45	4.53	0.11
Cash Income Taxes Paid	2.07	2.86	10	5.31	3.83	2.16

This table details how cash moves in and out of Cytek Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	33	3.38	1.51	8.78	-16	-64	-3.45	-20	18	-2.43	-25
Net Cash From Operating Activities	-4.24	9.51	3.96	6.20	13	2.00	-0.13	0.11	-3.90	-0.77	-2.74
Net Cash From Continuing Operating Activities	-4.24	12	3.96	6.20	13	2.00	-0.13	0.11	-3.90	-0.77	-2.74
Net Income / (Loss) Continuing Operations	-6.46	5.50	-6.17	-10	0.94	9.64	-11	-5.58	-5.48	-44	-19
Consolidated Net Income / (Loss)	-6.46	5.50	-6.17	-10	0.94	9.64	-11	-5.58	-5.48	-44	-19
Depreciation Expense	1.77	1.63	1.70	1.81	1.85	1.85	1.88	1.89	1.92	1.90	1.87
Amortization Expense	-0.77	-	-0.44	-0.51	-0.29	-0.69	-0.48	-0.52	-0.21	-0.07	-0.31
Non-Cash Adjustments To Reconcile Net Income	6.49	2.13	7.02	7.23	7.46	-3.62	7.19	7.16	6.06	2.23	5.76
Changes in Operating Assets and Liabilities, net	-5.27	-0.43	1.85	8.11	3.26	-5.18	2.69	-2.84	-6.19	39	8.82
Net Cash From Investing Activities	43	29	-5.75	2.02	-16	-63	9.45	-16	19	-1.84	-27
Net Cash From Continuing Investing Activities	43	29	-5.75	2.02	-16	-63	9.45	-16	19	-1.84	-27
Purchase of Property, Plant & Equipment	-1.33	-1.54	-0.57	-1.05	-1.01	-0.89	-0.85	-1.58	-0.66	-1.00	-2.17
Acquisitions	-0.06	-0.06	-0.06	-0.15	0.01	-0.48	-0.00	-0.07	0.00	-0.03	-0.03
Purchase of Investments	-23	-23	-77	-37	-53	-107	-60	-81	-60	-77	-96
Sale of Property, Plant & Equipment	-	-	0.00	-	0.02	0.19	0.03	0.02	0.00	0.20	0.01
Sale and/or Maturity of Investments	68	54	72	40	38	45	70	66	79	76	71
Net Cash From Financing Activities	-8.27	-34	1.61	-1.71	-12	-3.64	-12	-2.60	1.94	-1.23	3.98
Net Cash From Continuing Financing Activities	-8.27	-36	1.61	-1.71	-12	-3.64	-12	-2.60	1.94	-1.23	3.98
Repayment of Debt	-0.14	-0.14	-0.14	-0.14	-0.14	-0.14	-1.52	-0.14	-0.15	-2.94	-0.87
Repurchase of Common Equity	-8.43	-35	0.00	-	-12	-6.99	-11	-4.51	0.03	0.03	0.00
Issuance of Debt	-	-	1.39	-0.00	0.01	2.79	0.69	1.39	2.09	1.42	5.07
Other Financing Activities, net	0.29	0.24	0.36	0.09	0.00	1.71	-0.09	-0.04	-0.03	-0.18	-0.22
Effect of Exchange Rate Changes	-	-	1.70	2.26	-0.94	1.52	-1.23	-0.92	0.85	1.41	0.65
Cash Income Taxes Paid	0.13	4.50	0.00	1.06	0.86	1.91	0.00	0.03	-	2.13	-3.75

This table presents Cytek Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	220	463	519	494	500	462
Total Current Assets	209	432	454	392	396	392
Cash & Equivalents	165	365	297	167	99	91
Short-Term Investments	-	0.00	45	95	179	171
Accounts Receivable	17	30	49	56	61	63
Inventories, net	23	32	48	61	44	48
Prepaid Expenses	2.50	5.18	13	13	14	20
Plant, Property, & Equipment, net	2.14	5.85	14	18	18	18
Total Noncurrent Assets	9.22	26	52	84	85	52
Goodwill	0.48	10	10	16	17	17
Intangible Assets	0.27	4.74	4.33	23	20	17
Other Noncurrent Operating Assets	1.09	1.67	17	14	15	18
Total Liabilities & Shareholders' Equity	220	463	519	494	500	462
Total Liabilities	42	58	94	101	104	120
Total Current Liabilities	27	33	49	56	68	78
Accounts Payable	2.94	3.03	4.81	3.03	5.53	6.41
Accrued Expenses	9.05	15	21	20	21	23
Current Deferred Revenue	3.67	7.08	13	23	25	29
Other Current Liabilities	11	7.82	10	10	15	19
Total Noncurrent Liabilities	15	25	45	45	36	42
Asset Retirement Reserve & Litigation Obligation	11	14	16	16	9.04	6.79
Noncurrent Deferred Revenue	3.46	9.79	13	15	16	18
Other Noncurrent Operating Liabilities	0.74	1.20	16	14	11	17
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-16	405	426	393	396	342
Total Preferred & Common Equity	-16	405	426	393	396	342
Total Common Equity	-16	405	426	393	396	342
Common Stock	6.51	424	443	424	431	441
Retained Earnings	-23	-20	-17	-29	-35	-102
Accumulated Other Comprehensive Income / (Loss)	0.07	0.90	-0.70	-1.28	0.02	2.24

This table presents Cytek Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	499	525	525	519	492	484	491	483	493	495	449
Total Current Assets	444	426	425	422	389	384	390	381	383	388	379
Cash & Equivalents	342	129	132	164	169	178	162	95	75	93	66
Short-Term Investments	-	170	167	124	101	99	116	170	187	168	197
Accounts Receivable	40	43	50	55	50	45	53	55	56	57	52
Inventories, net	49	70	66	67	55	50	47	45	49	52	50
Prepaid Expenses	13	11	11	12	13	12	13	15	15	18	15
Plant, Property, & Equipment, net	7.84	16	16	17	18	18	19	18	18	18	20
Total Noncurrent Assets	48	83	85	80	85	82	83	84	92	88	49
Goodwill	10	19	19	16	16	16	16	17	17	17	17
Intangible Assets	4.49	25	24	24	22	21	20	19	19	18	16
Other Noncurrent Operating Assets	19	16	15	15	14	14	15	14	21	16	17
Total Liabilities & Shareholders' Equity	499	525	525	519	492	484	491	483	493	495	449
Total Liabilities	83	101	101	104	99	95	106	103	116	116	121
Total Current Liabilities	41	57	54	59	56	52	63	68	73	75	81
Accounts Payable	5.64	5.28	3.08	4.71	3.73	3.19	5.39	6.25	6.85	7.63	6.74
Accrued Expenses	17	20	20	21	18	15	21	19	22	20	20
Current Deferred Revenue	12	18	21	23	23	24	25	28	28	29	30
Other Current Liabilities	7.12	13	10	10	11	9.73	11	15	17	19	24
Total Noncurrent Liabilities	41	45	47	45	44	42	43	35	42	41	41
Asset Retirement Reserve & Litigation Obligation	15	16	16	16	17	17	17	8.82	8.48	8.16	6.64
Noncurrent Deferred Revenue	10	13	16	15	15	14	15	16	17	16	18
Other Noncurrent Operating Liabilities	16	16	15	14	12	11	11	11	17	17	16
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	417	423	424	416	393	389	385	380	378	379	328
Total Preferred & Common Equity	417	423	424	416	393	389	385	380	378	379	328
Total Common Equity	417	423	424	416	393	389	385	380	378	379	328
Common Stock	438	448	454	452	430	435	430	427	430	435	446
Retained Earnings	-21	-24	-28	-35	-35	-46	-45	-47	-52	-58	-121
Accumulated Other Comprehensive Income / (Loss)	-0.53	-0.59	-1.76	-1.58	-1.55	-0.20	0.10	-0.61	-0.04	0.82	2.37

This table displays calculated financial ratios and metrics derived from Cytek Biosciences' official financial filings.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-
Revenue Growth	0.00%	37.82%	28.20%	17.67%	3.85%	0.52%
EBITDA Growth	0.00%	-41.85%	-45.94%	-391.97%	23.01%	-134.50%
EBIT Growth	0.00%	-47.93%	-110.30%	-2,451.02%	19.90%	-96.66%
NOPAT Growth	0.00%	-74.59%	-176.19%	-448.06%	26.30%	-96.77%
Net Income Growth	0.00%	-84.41%	-17.94%	-589.05%	50.44%	-1,005.30%
EPS Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	0.00%	-69.45%	-364.17%	143.18%	380.57%	-118.46%
Free Cash Flow Firm Growth	0.00%	0.00%	-85.09%	-54.26%	97.23%	595.65%
Invested Capital Growth	0.00%	234.92%	99.91%	59.91%	-9.57%	-31.94%
Revenue Q/Q Growth	0.00%	0.00%	25.87%	5.41%	-0.38%	2.37%
EBITDA Q/Q Growth	0.00%	0.00%	123.01%	20.47%	-13.62%	-47.51%
EBIT Q/Q Growth	0.00%	0.00%	96.90%	4.22%	2.54%	-38.70%
NOPAT Q/Q Growth	0.00%	0.00%	78.56%	-0.80%	13.20%	-26.97%
Net Income Q/Q Growth	0.00%	0.00%	203.54%	12.81%	40.74%	-418.98%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	-57.22%	5.74%	169.16%	-22.85%	-144.32%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	4.92%	-157.34%	129.79%
Invested Capital Q/Q Growth	0.00%	0.00%	8.68%	2.21%	9.47%	-31.35%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	55.70%	61.86%	61.56%	56.69%	55.43%	51.84%
EBITDA Margin	16.43%	6.93%	2.92%	-7.25%	-5.38%	-12.55%
Operating Margin	14.71%	7.16%	-1.10%	-14.43%	-10.24%	-20.04%
EBIT Margin	15.78%	5.96%	-0.48%	-10.39%	-8.01%	-15.67%
Profit (Net Income) Margin	20.91%	2.37%	1.51%	-6.29%	-3.00%	-33.02%
Tax Burden Percent	134.52%	50.98%	197.14%	77.33%	105.61%	222.98%
Interest Burden Percent	98.48%	77.82%	-160.31%	78.35%	35.49%	94.48%
Effective Tax Rate	-34.52%	49.02%	-97.14%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	150.95%	17.64%	-5.82%	-18.40%	-11.58%	-28.55%
ROIC Less NNEP Spread (ROIC-NNEP)	150.33%	18.25%	-7.52%	-20.82%	-14.67%	-14.36%
Return on Net Nonoperating Assets (RNNOA)	-140.06%	-16.60%	6.42%	15.44%	10.05%	10.50%
Return on Equity (ROE)	10.89%	1.04%	0.60%	-2.97%	-1.53%	-18.05%
Cash Return on Invested Capital (CROIC)	0.00%	-90.39%	-72.45%	-64.50%	-1.52%	9.46%
Operating Return on Assets (OROA)	6.66%	2.23%	-0.16%	-3.96%	-3.23%	-6.57%
Return on Assets (ROA)	8.82%	0.89%	0.51%	-2.40%	-1.21%	-13.85%
Return on Common Equity (ROCE)	-0.98%	0.69%	0.60%	-2.97%	-1.53%	-18.05%
Return on Equity Simple (ROE_SIMPLE)	-121.11%	0.75%	0.58%	-3.09%	-1.52%	0.00%
Net Operating Profit after Tax (NOPAT)	18	4.67	-3.56	-19	-14	-28
NOPAT Margin	19.79%	3.65%	-2.17%	-10.10%	-7.17%	-14.03%
Net Nonoperating Expense Percent (NNEP)	0.62%	-0.62%	1.70%	2.42%	3.09%	-14.19%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-0.84%	-4.96%	-3.63%	-8.27%
Cost of Revenue to Revenue	44.30%	38.14%	38.44%	43.31%	44.57%	48.16%
SG&A Expenses to Revenue	10.09%	16.28%	21.15%	22.78%	21.51%	29.25%
R&D to Revenue	14.75%	19.10%	21.25%	22.87%	19.66%	18.10%
Operating Expenses to Revenue	40.99%	54.70%	62.66%	71.12%	65.67%	71.89%
Earnings before Interest and Taxes (EBIT)	15	7.63	-0.79	-20	-16	-32
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	15	8.87	4.80	-14	-11	-25
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	5.38	3.24	3.15	2.11	1.89
Price to Tangible Book Value (P/TBV)	0.00	5.59	3.35	3.49	2.33	2.10
Price to Revenue (P/Rev)	2.67	17.06	8.39	6.40	4.17	3.20
Price to Earnings (P/E)	76.99	0.00	534.49	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.30%	0.00%	0.19%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	22.66	44.59	12.67	7.47	4.74	4.79
Enterprise Value to Revenue (EV/Rev)	2.97	14.21	6.30	5.04	2.78	1.91
Enterprise Value to EBITDA (EV/EBITDA)	18.08	204.89	215.35	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	18.82	238.24	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	15.01	389.42	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	18.20	392.61	0.00	184.33	21.99	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	41.01
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.93	-0.91	-0.85	-0.74	-0.69	-0.73
Leverage Ratio	1.23	1.17	1.18	1.24	1.26	1.30
Compound Leverage Factor	1.22	0.91	-1.90	0.97	0.45	1.23
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	108.99%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-8.99%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	5.05	23.91	10.00	8.30	5.82	3.95
Noncontrolling Interest Sharing Ratio	108.99%	33.29%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	7.86	13.01	9.26	6.97	5.86	5.04
Quick Ratio	6.87	11.89	7.95	5.66	5.00	4.16
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-24	-44	-68	-1.89	9.37
Operating Cash Flow to CapEx	979.70%	106.10%	-125.47%	112.65%	784.03%	-122.29%
Free Cash Flow to Firm to Interest Expense	0.00	-13.74	-17.21	-32.99	0.00	19.76
Operating Cash Flow to Interest Expense	45.51	2.66	-4.75	2.55	0.00	-9.89
Operating Cash Flow Less CapEx to Interest Expense	40.87	0.15	-8.54	0.29	0.00	-17.97
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.42	0.37	0.33	0.38	0.40	0.42
Accounts Receivable Turnover	5.46	5.47	4.17	3.68	3.44	3.27
Inventory Turnover	1.79	1.77	1.57	1.53	1.71	2.10
Fixed Asset Turnover	43.38	32.02	16.80	12.03	11.02	11.20
Accounts Payable Turnover	13.97	16.33	16.09	21.33	20.87	16.25
Days Sales Outstanding (DSO)	66.80	66.68	87.47	99.08	106.08	111.49
Days Inventory Outstanding (DIO)	204.27	206.37	232.46	238.05	214.00	173.64
Days Payable Outstanding (DPO)	26.13	22.35	22.69	17.11	17.49	22.45
Cash Conversion Cycle (CCC)	244.94	250.70	297.25	320.02	302.60	262.68
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	12	41	81	130	118	80
Invested Capital Turnover	7.63	4.83	2.68	1.82	1.62	2.03
Increase / (Decrease) in Invested Capital	0.00	29	41	49	-12	-38
Enterprise Value (EV)	276	1,818	1,033	973	558	384
Market Capitalization	248	2,182	1,377	1,236	836	646
Book Value per Share	($0.55)	$3.03	$3.16	$2.90	$3.07	$2.67
Tangible Book Value per Share	($0.58)	$2.92	$3.05	$2.61	$2.79	$2.41
Total Capital	178	405	426	393	396	342
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-166	-365	-344	-263	-278	-262
Capital Expenditures (CapEx)	1.55	4.36	9.75	4.69	3.24	3.83
Debt-free, Cash-free Net Working Capital (DFCFNWC)	16	34	61	73	51	53
Debt-free Net Working Capital (DFNWC)	182	399	405	336	329	314
Net Working Capital (NWC)	182	399	405	336	329	314
Net Nonoperating Expense (NNE)	-1.04	1.64	-6.04	-7.34	-8.35	38
Net Nonoperating Obligations (NNO)	-166	-365	-344	-263	-278	-262
Total Depreciation and Amortization (D&A)	0.60	1.24	5.58	6.05	5.28	6.30
Debt-free, Cash-free Net Working Capital to Revenue	17.20%	26.52%	37.15%	37.87%	25.39%	26.14%
Debt-free Net Working Capital to Revenue	196.13%	311.49%	246.88%	173.99%	164.02%	155.93%
Net Working Capital to Revenue	196.13%	311.49%	246.88%	173.99%	164.02%	155.93%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	0.00	76.74M	134.51M	135.28M	130.61M	127.75M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	0.00	81.54M	138.56M	135.28M	130.61M	127.75M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	134.08M	135.43M	130.82M	128.10M	128.55M
Normalized Net Operating Profit after Tax (NOPAT)	9.56	4.67	-1.26	-19	-14	-28
Normalized NOPAT Margin	10.30%	3.65%	-0.77%	-10.10%	-7.17%	-14.03%
Pre Tax Income Margin	15.54%	4.64%	0.77%	-8.14%	-2.84%	-14.81%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	44.00	4.38	-0.31	-9.68	0.00	-66.63
NOPAT to Interest Expense	55.18	2.68	-1.38	-9.41	0.00	-59.64
EBIT Less CapEx to Interest Expense	39.36	1.88	-4.09	-11.95	0.00	-74.72
NOPAT Less CapEx to Interest Expense	50.53	0.17	-5.17	-11.68	0.00	-67.72
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	-363.44%	-358.99%	-22.65%

This table displays calculated financial ratios and metrics derived from Cytek Biosciences' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	128,097,379.00	126,659,196.00	127,223,778.00	-	128,550,136.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	128,097,379.00	126,659,196.00	127,223,778.00	-	128,550,136.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-0.09	-0.04	-0.04	-	-0.15
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	18.59%	20.48%	20.96%	-6.19%	7.29%	-1.30%	-7.59%	-2.18%	1.54%	8.12%	6.46%
EBITDA Growth	-349.94%	18.35%	9.00%	-24.97%	109.63%	-1.11%	-16.63%	22.70%	-1,612.56%	-175.59%	-61.91%
EBIT Growth	-669.62%	40.60%	5.70%	-14.63%	77.80%	13.67%	-15.86%	18.33%	-578.31%	-253.51%	-55.87%
NOPAT Growth	-475.96%	-339.81%	11.74%	6.57%	-466.55%	1,632.15%	-39.51%	-24.59%	74.73%	-240.36%	-23.29%
Net Income Growth	-497.05%	48.01%	9.37%	-137.78%	114.58%	75.21%	-84.83%	46.49%	-682.15%	-557.13%	-65.46%
EPS Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	43.51%	53.59%	38.45%	317.68%	411.89%	-79.01%	-103.16%	-98.26%	-129.48%	-138.61%	-2,088.80%
Free Cash Flow Firm Growth	-20.36%	-20.54%	90.44%	110.63%	90.15%	131.15%	71.54%	-248.06%	-178.22%	120.91%	1,639.02%
Invested Capital Growth	70.04%	59.91%	0.52%	-10.74%	-15.57%	-9.57%	-6.68%	3.27%	8.53%	-31.94%	-42.62%
Revenue Q/Q Growth	-3.41%	21.32%	-22.97%	3.92%	10.47%	11.60%	-27.87%	10.00%	14.67%	18.83%	-28.98%
EBITDA Q/Q Growth	26.56%	211.27%	-284.54%	17.13%	105.66%	1,042.12%	-317.64%	45.08%	-10.79%	42.92%	-366.19%
EBIT Q/Q Growth	29.44%	158.67%	-424.10%	14.56%	86.34%	400.43%	-430.35%	39.77%	-13.48%	32.01%	-235.42%
NOPAT Q/Q Growth	29.66%	95.95%	-4,027.33%	20.56%	-326.56%	110.96%	-475.81%	29.06%	13.48%	39.15%	-230.11%
Net Income Q/Q Growth	-47.13%	185.24%	-212.10%	-69.14%	109.02%	924.65%	-218.25%	51.03%	1.88%	-704.60%	57.20%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-48.74%	324.39%	-58.40%	56.79%	113.10%	-84.90%	-106.26%	186.40%	-3,709.26%	80.22%	-254.86%
Free Cash Flow Firm Q/Q Growth	19.13%	14.04%	83.39%	192.00%	-174.94%	371.97%	-115.18%	-378.52%	-40.82%	315.94%	5.77%
Invested Capital Q/Q Growth	1.72%	2.21%	-6.25%	-8.42%	-3.78%	9.47%	-3.26%	1.34%	1.13%	-31.35%	-18.44%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	56.62%	56.75%	51.30%	54.56%	56.32%	58.55%	48.62%	52.34%	52.69%	52.92%	48.16%
EBITDA Margin	-8.78%	8.05%	-19.29%	-15.38%	0.79%	8.07%	-24.34%	-12.16%	-11.74%	-5.64%	-37.02%
Operating Margin	-13.38%	-0.23%	-23.93%	-18.29%	-8.25%	5.20%	-36.12%	-23.30%	-17.58%	-9.00%	-41.83%
EBIT Margin	-10.86%	5.25%	-22.09%	-18.17%	-2.25%	6.05%	-27.70%	-15.17%	-15.01%	-8.59%	-40.55%
Profit (Net Income) Margin	-13.45%	9.45%	-13.75%	-22.38%	1.83%	16.78%	-27.50%	-12.24%	-10.48%	-70.93%	-42.75%
Tax Burden Percent	154.27%	133.86%	68.60%	145.20%	599.36%	93.41%	101.21%	82.41%	70.51%	1,093.43%	108.59%
Interest Burden Percent	80.30%	134.43%	90.74%	84.86%	-13.57%	296.95%	98.11%	97.96%	98.99%	75.54%	97.07%
Effective Tax Rate	0.00%	-33.86%	0.00%	0.00%	-499.36%	6.59%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-16.93%	-0.57%	-27.60%	-21.34%	-84.60%	7.84%	-42.19%	-28.12%	-21.58%	-12.82%	-66.64%
ROIC Less NNEP Spread (ROIC-NNEP)	-16.31%	-2.44%	-28.07%	-19.79%	-93.94%	5.30%	-41.85%	-28.80%	-21.93%	2.07%	-64.39%
Return on Net Nonoperating Assets (RNNOA)	12.34%	1.81%	19.69%	14.02%	66.36%	-3.64%	29.05%	20.26%	15.49%	-1.51%	48.06%
Return on Equity (ROE)	-4.59%	1.24%	-7.91%	-7.32%	-18.25%	4.20%	-13.14%	-7.86%	-6.09%	-14.33%	-18.59%
Cash Return on Invested Capital (CROIC)	-70.97%	-64.50%	-15.69%	-3.89%	2.80%	-1.52%	-7.76%	-19.75%	-28.01%	9.46%	19.93%
Operating Return on Assets (OROA)	-3.90%	2.00%	-8.73%	-7.12%	-0.89%	2.44%	-11.20%	-6.09%	-5.99%	-3.60%	-17.77%
Return on Assets (ROA)	-4.84%	3.60%	-5.43%	-8.77%	0.73%	6.77%	-11.12%	-4.91%	-4.18%	-29.74%	-18.73%
Return on Common Equity (ROCE)	-4.59%	1.24%	-7.91%	-7.32%	-18.25%	4.20%	-13.14%	-7.86%	-6.09%	-14.33%	-18.59%
Return on Equity Simple (ROE_SIMPLE)	-3.35%	0.00%	-2.93%	-4.51%	-2.64%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-4.49	-0.18	-7.51	-5.97	-25	2.79	-10	-7.44	-6.43	-3.92	-13
NOPAT Margin	-9.36%	-0.31%	-16.75%	-12.80%	-49.44%	4.85%	-25.29%	-16.31%	-12.30%	-6.30%	-29.28%
Net Nonoperating Expense Percent (NNEP)	-0.62%	1.87%	0.47%	-1.55%	9.33%	2.54%	-0.34%	0.69%	0.35%	-14.89%	-2.25%
Return On Investment Capital (ROIC_SIMPLE)	-	-0.05%	-	-	-	0.70%	-2.76%	-1.97%	-1.70%	-1.15%	-3.94%
Cost of Revenue to Revenue	43.38%	43.25%	48.70%	45.44%	43.68%	41.45%	51.38%	47.66%	47.31%	47.08%	51.84%
SG&A Expenses to Revenue	21.56%	18.47%	25.43%	25.09%	21.25%	15.78%	31.11%	29.67%	30.83%	26.37%	41.84%
R&D to Revenue	23.27%	18.67%	21.84%	21.45%	19.19%	16.92%	23.46%	19.35%	17.13%	14.42%	21.76%
Operating Expenses to Revenue	70.00%	56.98%	75.23%	72.86%	64.57%	53.35%	84.74%	75.63%	70.26%	61.92%	89.99%
Earnings before Interest and Taxes (EBIT)	-5.21	3.06	-9.91	-8.47	-1.16	3.48	-11	-6.92	-7.85	-5.34	-18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-4.21	4.69	-8.65	-7.17	0.41	4.64	-10	-5.54	-6.14	-3.51	-16
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.81	3.15	2.24	1.88	1.89	2.11	1.35	1.14	1.17	1.89	1.71
Price to Tangible Book Value (P/TBV)	2.01	3.49	2.48	2.08	2.09	2.33	1.50	1.26	1.28	2.10	1.90
Price to Revenue (P/Rev)	4.11	6.40	4.37	3.70	3.62	4.17	2.61	2.20	2.24	3.20	2.75
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	3.64	7.47	4.97	4.07	4.19	4.74	2.18	1.46	1.54	4.79	4.58
Enterprise Value to Revenue (EV/Rev)	2.54	5.04	3.03	2.30	2.24	2.78	1.26	0.86	0.91	1.91	1.47
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	236.84	184.33	95.20	29.50	13.70	21.99	11.65	11.09	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	136.73	0.00	0.00	0.00	0.00	41.01	16.75
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.76	-0.74	-0.70	-0.71	-0.71	-0.69	-0.69	-0.70	-0.71	-0.73	-0.75
Leverage Ratio	1.22	1.24	1.25	1.24	1.26	1.26	1.26	1.27	1.29	1.30	1.32
Compound Leverage Factor	0.98	1.67	1.13	1.05	-0.17	3.74	1.24	1.25	1.28	0.98	1.28
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	5.41	8.46	6.35	5.69	5.21	5.95	3.97	3.19	3.22	4.14	3.52
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	7.20	6.97	6.99	7.33	6.21	5.86	5.62	5.22	5.17	5.04	4.69
Quick Ratio	5.85	5.66	5.77	6.14	5.26	5.00	4.74	4.34	4.23	4.16	3.88
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-57	-49	-8.14	7.49	-5.61	15	-2.32	-11	-16	34	36
Operating Cash Flow to CapEx	-318.72%	617.66%	697.88%	589.17%	1,335.45%	284.07%	-15.32%	6.95%	-594.21%	-95.66%	-126.55%
Free Cash Flow to Firm to Interest Expense	-95.82	-124.38	-18.46	55.90	-47.17	0.00	-7.96	-26.79	-31.61	0.00	136.13
Operating Cash Flow to Interest Expense	-7.12	24.14	8.97	46.30	111.10	0.00	-0.43	0.26	-7.89	0.00	-10.44
Operating Cash Flow Less CapEx to Interest Expense	-9.36	20.23	7.69	38.44	102.78	0.00	-3.23	-3.49	-9.22	0.00	-18.69
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.36	0.38	0.40	0.39	0.40	0.40	0.40	0.40	0.40	0.42	0.44
Accounts Receivable Turnover	3.85	3.68	4.30	4.19	3.72	3.44	3.74	3.89	3.60	3.27	3.82
Inventory Turnover	1.33	1.53	1.44	1.54	1.60	1.71	1.77	1.80	1.86	2.10	2.07
Fixed Asset Turnover	14.50	12.03	11.88	11.73	11.20	11.02	10.92	10.75	10.77	11.20	10.66
Accounts Payable Turnover	14.95	21.33	19.85	28.39	17.96	20.87	17.81	17.79	14.07	16.25	15.19
Days Sales Outstanding (DSO)	94.72	99.08	84.90	87.01	97.99	106.08	97.56	93.91	101.31	111.49	95.58
Days Inventory Outstanding (DIO)	274.21	238.05	253.67	237.36	228.71	214.00	205.70	203.34	196.14	173.64	176.07
Days Payable Outstanding (DPO)	24.42	17.11	18.39	12.86	20.32	17.49	20.49	20.51	25.94	22.45	24.04
Cash Conversion Cycle (CCC)	344.51	320.02	320.18	311.52	306.38	302.60	282.76	276.74	271.51	262.68	247.61
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	128	130	122	112	108	118	114	116	117	80	65
Invested Capital Turnover	1.81	1.82	1.65	1.67	1.71	1.62	1.67	1.72	1.75	2.03	2.28
Increase / (Decrease) in Invested Capital	53	49	0.63	-13	-20	-12	-8.17	3.65	9.18	-38	-49
Enterprise Value (EV)	465	973	607	455	451	558	248	169	180	384	300
Market Capitalization	753	1,236	878	733	729	836	514	431	441	646	562
Book Value per Share	$3.05	$2.90	$3.00	$2.96	$2.93	$3.07	$2.96	$2.98	$2.98	$2.67	$2.55
Tangible Book Value per Share	$2.75	$2.61	$2.71	$2.68	$2.65	$2.79	$2.68	$2.70	$2.71	$2.41	$2.30
Total Capital	416	393	393	389	385	396	380	378	379	342	328
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-288	-263	-270	-277	-278	-278	-266	-262	-262	-262	-262
Capital Expenditures (CapEx)	1.33	1.54	0.57	1.05	0.99	0.70	0.82	1.55	0.66	0.81	2.16
Debt-free, Cash-free Net Working Capital (DFCFNWC)	76	73	63	54	50	51	47	48	52	53	36
Debt-free Net Working Capital (DFNWC)	364	336	333	332	327	329	313	310	313	314	298
Net Working Capital (NWC)	364	336	333	332	327	329	313	310	313	314	298
Net Nonoperating Expense (NNE)	1.96	-5.69	-1.34	4.47	-26	-6.85	0.92	-1.85	-0.96	40	5.94
Net Nonoperating Obligations (NNO)	-288	-263	-270	-277	-278	-278	-266	-262	-262	-262	-262
Total Depreciation and Amortization (D&A)	1.00	1.63	1.26	1.30	1.56	1.16	1.39	1.37	1.71	1.83	1.56
Debt-free, Cash-free Net Working Capital to Revenue	41.29%	37.87%	31.20%	27.55%	24.64%	25.39%	23.95%	24.25%	26.19%	26.14%	17.70%
Debt-free Net Working Capital to Revenue	198.57%	173.99%	165.89%	167.77%	162.71%	164.02%	158.75%	157.91%	159.17%	155.93%	146.14%
Net Working Capital to Revenue	198.57%	173.99%	165.89%	167.77%	162.71%	164.02%	158.75%	157.91%	159.17%	155.93%	146.14%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	136.17M	135.28M	130.92M	131.44M	131.00M	130.61M	128.34M	126.93M	127.55M	127.75M	128.70M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	136.17M	135.28M	130.92M	131.44M	132.79M	130.61M	128.34M	126.93M	127.55M	127.75M	128.70M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	135.55M	130.82M	131.27M	131.51M	128.81M	128.10M	126.66M	127.22M	127.86M	128.55M	129.14M
Normalized Net Operating Profit after Tax (NOPAT)	-4.49	-0.10	-7.51	-5.97	-2.97	2.79	-10	-7.44	-6.43	-3.92	-13
Normalized NOPAT Margin	-9.36%	-0.16%	-16.75%	-12.80%	-5.77%	4.85%	-25.29%	-16.31%	-12.30%	-6.30%	-29.28%
Pre Tax Income Margin	-8.72%	7.06%	-20.05%	-15.42%	0.30%	17.96%	-27.18%	-14.86%	-14.86%	-6.49%	-39.36%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-8.76	7.76	-22.47	-63.19	-9.72	0.00	-39.46	-16.71	-15.89	0.00	-68.31
NOPAT to Interest Expense	-7.55	-0.46	-17.04	-44.54	-213.96	0.00	-36.02	-17.96	-13.03	0.00	-49.33
EBIT Less CapEx to Interest Expense	-11.00	3.85	-23.76	-71.05	-18.04	0.00	-42.26	-20.46	-17.21	0.00	-76.56
NOPAT Less CapEx to Interest Expense	-9.79	-4.37	-18.32	-52.40	-222.28	0.00	-38.83	-21.72	-14.35	0.00	-57.58
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-363.44%	0.00%	-261.11%	-485.89%	-358.99%	-286.48%	-532.30%	-172.37%	-22.65%	-6.01%

Financials Breakdown Chart

Key Financial Trends

Cytek Biosciences (NASDAQ: CTKB) showed a mixed but improving picture in the most recent quarter, with revenue growth returning in Q1 2026, but the company still posted a sizable loss and continued to burn cash from operations.

Revenue rose to $44.1 million in Q1 2026 from $41.5 million in Q1 2025, showing a modest year-over-year recovery.
Gross profit improved to $21.3 million, with gross margin staying strong at roughly 48% of revenue.
The balance sheet remains solid, with $65.7 million in cash and equivalents plus $196.6 million in short-term investments.
Total equity was $327.6 million, which is well above total liabilities of $121.5 million, indicating a healthy capital base.
The company still generated significant non-operating income from investments, which helped offset operating losses.
Operating expenses remain elevated, especially SG&A, marketing, and R&D, which together exceeded gross profit in Q1 2026.
Inventory and receivables remain material components of current assets, so working capital efficiency will matter going forward.
Cytek reported an operating loss of $18.5 million in Q1 2026, worse than the revenue recovery would suggest.
Net loss widened to $18.9 million from $11.4 million in Q1 2025.
Operating cash flow was still negative at -$2.7 million in Q1 2026, so the business is not yet self-funding its operations.

Looking at the broader trend over the last four years, Cytek’s revenue appears to be volatile rather than steadily growing. Quarterly revenue ranged from the low $40 millions to the low $60 millions, but profitability has been inconsistent. The company had periods of positive net income, including late 2024, yet most recent quarters have reverted to losses.

One encouraging sign is liquidity. Cytek has maintained a large cash and investment position, which gives it flexibility to absorb losses and continue investing in the business. That said, the company has also been using cash on operations in several recent quarters, so investors should watch whether expense growth slows and operating cash flow turns sustainably positive.

Bottom line: CTKB has a strong balance sheet and enough liquidity to weather near-term weakness, but the core business still needs better operating leverage. For retail investors, the key question is whether revenue growth can reaccelerate faster than expenses.

07/21/26 01:02 AM ETAI Generated. May Contain Errors.

Cytek Biosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Cytek Biosciences' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Cytek Biosciences' net income appears to be on an upward trend, with a most recent value of -$66.54 million in 2025, falling from $19.41 million in 2020. The previous period was -$6.02 million in 2024. Check out Cytek Biosciences' forecast to explore projected trends and price targets.

Cytek Biosciences' total operating income in 2025 was -$40.38 million, based on the following breakdown:

Total Gross Profit: $104.46 million
Total Operating Expenses: $144.84 million

Over the last 5 years, Cytek Biosciences' total revenue changed from $92.84 million in 2020 to $201.49 million in 2025, a change of 117.0%.

Cytek Biosciences' total liabilities were at $119.80 million at the end of 2025, a 15.5% increase from 2024, and a 187.4% increase since 2020.

In the past 5 years, Cytek Biosciences' cash and equivalents has ranged from $90.85 million in 2025 to $364.62 million in 2021, and is currently $90.85 million as of their latest financial filing in 2025.

Over the last 5 years, Cytek Biosciences' book value per share changed from -0.55 in 2020 to 2.67 in 2025, a change of -585.7%.

Related Companies

Financial statements for NASDAQ:CTKB last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytek Biosciences (CTKB) Financials

Financials Breakdown Chart

Key Financial Trends

Cytek Biosciences Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cytek Biosciences (CTKB) Financials

Annual Income Statements for Cytek Biosciences

Quarterly Income Statements for Cytek Biosciences

Annual Cash Flow Statements for Cytek Biosciences

Quarterly Cash Flow Statements for Cytek Biosciences

Annual Balance Sheets for Cytek Biosciences

Quarterly Balance Sheets for Cytek Biosciences

Annual Metrics And Ratios for Cytek Biosciences

Quarterly Metrics And Ratios for Cytek Biosciences

Financials Breakdown Chart

Key Financial Trends

Cytek Biosciences Financials - Frequently Asked Questions

When does Cytek Biosciences' financial year end?

How has Cytek Biosciences' net income changed over the last 5 years?

What is Cytek Biosciences' operating income?

How has Cytek Biosciences' revenue changed over the last 5 years?

How much debt does Cytek Biosciences have?

How much cash does Cytek Biosciences have?

How has Cytek Biosciences' book value per share changed over the last 5 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools